Increased India Drug Exports To U.S. Draw Stepped-Up Plant Inspections
This article was originally published in PharmAsia News
India drug exports to the U.S. may be increasing sales and profits, but they also have elicited greater attention to their safety, leading in some cases to rejection of products from certain plants.
You may also be interested in...
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.